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Abstract Mass spectrometry-based serum metabolic
profiling is a promising tool to analyse complex cancer
associated metabolic alterations, which may broaden our
pathophysiological understanding of the disease and may
function as a source of new cancer-associated biomarkers.
Highly standardized serum samples of patients suffering
from colon cancer (n = 59) and controls (n = 58) were
collected at the University Hospital Leipzig. We based our
investigations on amino acid screening profiles using
electrospray tandem-mass spectrometry. Metabolic profiles
were evaluated using the Analyst 1.4.2 software. General,
comparative and equivalence statistics were performed by
R 2.12.2. 11 out of 26 serum amino acid concentrations
were significantly different between colorectal cancer
patients and healthy controls. We found a model including
CEA, glycine, and tyrosine as best discriminating and
superior to CEA alone with an AUROC of 0.878 (95% CI
0.815–0.941). Our serum metabolic profiling in colon
cancer revealed multiple significant disease-associated
alterations in the amino acid profile with promising diag-
nostic power. Further large-scale studies are necessary to
elucidate the potential of our model also to discriminate
between cancer and potential differential diagnoses. In
conclusion, serum glycine and tyrosine in combination
with CEA are superior to CEA for the discrimination
between colorectal cancer patients and controls.
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1 Introduction
Metabolomics, which is a sub-field of the new “omics”
technologies, allows the systemic study of small-molecular
weight metabolites expressed in a biological system
(Ceglarek et al. 2009). These metabolites belong to diverse
chemical classes such as amino acids, organic acids, fatty
acids, or sugars (Chan et al. 2009; Dettmer et al. 2007).
They are the final down-stream products of transcription
and translation and thus are closest to the phenotype
(Mamas et al. 2011). Hence, metabolomics promise to
serve an important role in bridging the genotype-phenotype
gap (Cascante and Marin 2008). In view of cancer disease
previous research has particularly focused on the under-
standing of transcriptional regulation of cancer-associated
gene expression, whereas less effort has been directed at
investigations of metabolic alterations (Cardoso et al.
2007). Meanwhile, new mass spectrometry-based tech-
niques allow a simultaneous and quantitative in-depth
analysis of different metabolomic profiles in various bio-
logical samples (Ceglarek et al. 2009). These new
approaches promise to enlighten the complex tumorigene-
sis associated metabolic alterations, which may accelerate
the discovery of new diagnostic, prognostic, and predictive
biomarkers. Despite this analytical evolution, however,
profound knowledge and understanding of cancer metab-
olism is still lacking. This holds especially true for
colorectal cancer (CRC), which is the third most common
cause of cancer mortality in developed countries with an
annual mortality of more than 500,000 cases (Herszenyi
and Tulassay 2011). Colorectal cancer is among the top ten
causes of death in Germany with an attributable fraction of
2% of all fatalities (DESTATIS, Statistisches Bundesamt
Deutschland 2009). Comprising 16% of all cancer cases it
is the second most common cancer type, and with 12–14%
also the second most common cause of cancer death.
Colonoscopy/sigmoidoscopy is still the “gold standard” in
detecting colorectal carcinoma and high-risk adenomas, but
its invasiveness, the experience of discomfort, the potential
risks of complications, and the resources needed for the
screening itself, when compared to FOBT, are disadvan-
tages of concern (Bretthauer 2010). In contrast, the
recommended iFOBT delivers sensitivity rates of 61–91%
(Duffy et al. 2011), which are far from being satisfactory.
Currently, there are no serum screening markers for CRC
available. Carcinoembryonic antigen (CEA), the tumor
marker of choice for CRC, is well suited for therapy
monitoring, but also lacks the sensitivity needed for
screening purposes (Shimwell et al. 2010). Earlier diag-
nosis of this cancer and early relapse monitoring after
initial therapy are probably the best available options to
improve patient survival. Established serum tumor markers
such as CEA are useful to monitor the course of disease on
and off treatment, but they lack the sensitivity and speci-
ficity criteria for screening stratification purposes (Tanaka
et al. 2010). In this regard, mass spectrometry-based met-
abolic profiling may be valuable for the identification of
new “disease signatures” and cancer-associated biomarkers.
Preceding metabolic investigations primarily aimed at the
discovery of metabolites significantly different between
controls and CRC patients in serum, urine, and tissue
(Wang et al. 2009) by applying standard test statistics [e.g.
Student’s t-test, Wilcoxon-test, or the PCA (Principal
Component Analysis)-based (O)PLS-DA (Ma et al. 2010;
Qiu et al. 2009)] and revealed several potential marker
metabolites. These preliminary results encouraged us to
investigate the serum amino acid profiles and their altera-
tions in CRC using a tandem mass-spectrometric approach
(Fiedler et al. 2004; Mueller et al. 2003). In our study, we
additionally considered two further aspects: to avoid pre-
analytical flaws (Issaq et al. 2011) we strictly adhered to
previously published protocols (Baumann et al. 2005;
Brauer et al. 2011) as well as standardized sample pro-
cessing (Ceglarek et al. 2002) and reporting (Fiehn et al.
2007). Second, to provide not only significant differences,
but—as a core task of laboratory medicine—also statisti-
cally sound statements on their diagnostic surplus value,
we additionally evaluated the markers we found and the
conventional tumor marker CEA with respect to non-
inferiority and superiority.
2 Materials and methods
2.1 Ethics statement
The study was approved by the ethics committee of the
Medical Faculty of the University of Leipzig [Reg. No.
013-2005] and fulfills the requirements of the Helsinki
declaration. All subjects gave written informed consent to
participate in the study.
2.2 Patients and samples
Patients with CRC (n = 59) and respective controls
(n = 58) were recruited at the University Hospital Leipzig
in the context of a previously published study (Fiedler et al.
2009). Subjects were matched according to age and gender.
Fasting blood sampling from patients was performed
before initiation of specific therapy. Healthy controls called
in for checkup showed no evidence of actual disease
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proven by physical examination and routine laboratory
testing (differentials, C-reactive protein (CRP), creatinine,
transaminases, alkaline phosphatase, γ-glutamyl transfer-
ase, bilirubin, tumor marker CEA). Venous serum samples
were collected and stored by standardized techniques and
protocols (Baumann et al. 2005; Brauer et al. 2011),
including puncture of the cubital vein, 30–60 min coagu-
lation at room temperature, centrifugation for 10 min at
1,400 g, immediate aliquotation and storage at –80°C until
analysis.
2.3 Chemicals, standards and consumables
2.3.1 Materials
Methanol and isopropanol (gradient grade) were purchased
from Merck (Darmstadt, Germany). The amino acid (AA)
isotopes labelled standard kits (NSK-A, NSK-B, Cambridge
Isotope Laboratories, Andover, USA) were used as internal
standard. Water (HPLC grade) was obtained from J. T.
Baker (Deventer, Netherlands). The derivatization reagent
3n butanolic HCl was made in-house by mixing 4:1 v/v of
1-butanol (for spectroscopy) from Merck (Darmstadt,
Germany) and acetyl chloride (p.a.) from Sigma-Aldrich
(Steinheim, Germany). 96-well polypropylene microtiter
plates were purchased from Greiner Bio-One (Frickenhau-
sen, Germany). Multifly needle sets and polypropylene
serum monovettes with clotting activators were also
obtained from Sarstedt. For sample storage 450 μl Cryo-
Tubes™ were purchased from Sarstedt (Nu¨mbrecht,
Germany).
2.4 Sample pretreatment
A sample derivatization protocol was used according to
our formerly described procedures (Brauer et al. 2011;
Ceglarek et al. 2002) to enhance the sensitivity of the mass
spectrometric detection and thereby being able to minimize
the sample volume (Harder et al. 2011). Serum samples
were diluted 1:10 with methanol for protein precipitation.
After centrifugation we placed 10 μl of the supernatant into
96 well polypropylene microtiter plates and diluted it with
100 μl of the internal standard solution. After evaporation
at 70°C for 40 min, we added 60 μl of 3n butanolic-HCL
for derivatization at 65°C for 18 min. Again, the residual
solution was evaporated at 70°C for 40 min and then
reconstituted with 150 μl of the mobile phase (1/1 v/v
isopropanol/water). After 15 min of gentle shaking of the
microtiter plate at room temperature, we analyzed the
samples by flow injection analysis (FIA)-MS/MS. We
aligned the samples in alternating series of 20 controls and
cases on two microtiter plates and measured them in one
analytical run on one day.
2.5 CEA
CEA was measured in serum samples by an electrochemi-
luminescence immunoassay (Roche, Germany) on Modular
analytics E 170 analyzer (Roche, Germany) according to the
manufacturer’s instructions.
2.6 Tandem mass spectrometry
An API 3000 tandem mass spectrometer (Applied Bio-
systems, Germany) using a Turbo Ion Spray Source (TIS)
in combination with a HTC Pal autosampler and a PE 200
microgradient pump was used for flow injection analysis
(FIA). 25 μl of the sample were directly injected at a flow
rate of 80 μl/min in an analysis time of 1.5 min. We
detected amino acids by a neutral loss scan of 102 in the
mass range of 130–280 or multiple reaction monitoring
(MRM). Quantitative analysis using internal standards was
performed for 26 amino acids using ChemoView™ 1.4.2
(Applied Biosystems, Darmstadt, Germany). A compre-
hensive overview of mass transitions, internal standards,
and performance data for the different amino acids can be
found in Brauer et al. (2011).
2.7 Statistical analysis
Statistical testing was performed using ‘R’ (R Development
Core Team 2008) with the packages ‘nortest’ (Gross 2006),
‘pROC’ (Robin et al. 2010, 2011), ‘BMA’ (Raftery et al.
2010), ‘car’ (Fox and Weisberg 2011), ‘care’ (Zuber and
Strimmer 2010a), ‘ltm’ (Rizopoulos 2010), ‘boot’ (Davison
and Hinkley 1997), ‘stats’, and ‘rattle’ (Graham 2009). To
test for normalitywe applied theAnderson–Darling test from
‘R’s ‘nortest’ package (Stephens 2006). Gender distribution
in the groups was evaluated applying Fisher’s exact test,
group-related differences for the remaining parameters by
Wilcoxon’s test (both from R’s ‘stats’-package). For boot-
strapping, we used ‘R’s ‘sample’ function as well as the
‘boot’ package [B = 999 runs with replacement, cf.
Carpenter and Bithell (2000)] to compute robust estimates
for the 95% confidence intervals (CIs) of the medians as well
as minima and maxima. For the CIs of the ROC curves and
area under the ROC curves (AUROCs) we employed
‘pROC’s built-in boot.n function (also with B = 999 runs).
Group-specific differences were evaluated by the Mann–
Whitney-U-test (*P \ 0.05; **P \ 0.001). Kendall’s
correlation plot (Fig. 1) was drawn with ‘rattle’ [see
Murdoch and Chow (1996) for details]. We computed point-
biserial correlation coefficients rpb by ‘R’s ‘ltm’ (Rizopoulos
2010) package, the significance levels thereof by the method
proposed by Israel (Israel 2008). ROC curve and AUROC
calculations were performed using ‘R’s ‘pROC’ pack-
age. Since we presumed that marker models including
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combinations of different amino acids and/or CEA might be
superior over single amino acids and/or CEA regarding their
selectivity, we also evaluated combined models. For this
purpose, we selected amino acids significantly different
between the groups (cf. Table 2) and, following power
transformation (In-Kwon and Johnson 2000), performed a
Principal Component Analysis [PCA, Eigenvalue \1,
applying ‘R’s ‘princomp’ function of the ‘stats’ package
(Venables and Ripley 2002)] thereon to minimize collin-
earities and to set up principal components for subsequent
regression analysis and AUROC evaluation. We used com-
binations of these principal components as well as the
concentrations of the significantly differing amino acids
together with CEA in binary logistic regression modeling
[package ‘BMA’, selection of the best fitting models and
penalizing overfitting via theBayesian InformationCriterion
(BIC), observing the degree of multicollinearity via the
Variance Inflation Factor (VIF), model validation via the
CAR score (defined as ‘the marginal correlations adjusted
for correlation among explanatory variables’ with the acro-
nym ‘CAR’ as an abbreviation for ‘Correlation-
Adjusted (marginal) coRrelation’) applying package ‘care’
for the respective number of predictors, cf. Zuber and
Strimmer (2010b)] to build predictors and to compare their
selectivity with the selectivity of CEA alone by AUROC
analysis in turn. Pvalues for the comparison of AUCs are
computed as proposed by DeLong et al. (1988) for AUCs
generated by the ‘pROC’ package [cf. Robin et al. (2010)].
‘Best’ thresholds determined by the Youden index were
computed using the ‘pROC’ package according to themethod
suggested by Perkins and Schisterman (2006). Non-inferior-
ity and superiority testing thereafter was performed applying
bootstrap techniques (B = 999, package ‘boot’) on ΔAUROC,
constructing CIs thereof, and testing for embracement of Δ0
by theΔAUROC’sCI according to themethods proposed byLiu
et al. (2006), Tunes da Silva et al. (2009), and Lesaffre (2008)
at a predefined δL level of 5% which we considered to be
medically reasonable (Mascha 2010) designing the study.
3 Results
For our investigations we collected serum samples of 59
(37m/22f) colorectal carcinoma patients and 58 [26m/32f;
P = not significant (n.s.)] healthy controls. Age, UICC
(Union Internationale Contre le Cancer) stagings of the
patients, and CEA concentrations are displayed in Table 1.
3.1 Descriptives
To generate robust estimators for the amino acid concen-
trations in the colorectal carcinoma patients and healthy
controls covering the value range and the 95% confidence
interval of the median for comparative studies, we applied
bootstrapping techniques—the resampling results are
summarized in Table 2 and displayed separately for both
groups. In total, we found 19 of 26 amino acids decreased
(11 thereof significantly) and 7 amino acids increased
Fig. 1 Correlation matrix plot
of the amino acid concentrations
[Kendall’s τb, circle denotes low
correlation and oval denotes
high correlation, positive,
negative, and neutral
correlations are displayed blue,
red, and white, respectively (see
Murdoch and Chow (1996) for
details)] to display the mutual
collinearities between amino
acid concentrations. The top
line (shaded) shows point
biserial correlations rpb and
significance levels for the
correlation of the respective
amino acid with the health state
(*P \ 0.05; **P \ 0.01;
***P \ 0.001)
Table 1 Baseline characteristics
Baseline characteristics Colon cancer
patients
Healthy
controls
Male/Female 37/22 26/32
Age (years; median, 2.5th–97.5th) 59 (45–90) 58 (38–75)
CEA (ng/ml; Median,
2.5th–97.5th)
3.5 (0.9–2387.0) 1.7 (0.6–3.7)
UICC staging (stage 1/2/3/4) 5/18/20/16 –
Baseline characteristics of the colorectal cancer and the healthy
control group. Both groups differed highly significant in their CEA
serum concentrations (P \ 0.001)
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Table 2 Median, minimum, maximum, and the 95% CI of the median for amino acids in colon cancer patients and controls
Colon cancer patients (n = 59) [μmol/l]a Controls (n = 58) [μmol/l]a
Median Range Median CI 95% Median Range Median CI 95%
Minimum Maximum Low High Minimum Maximum Low High
Glutamine (Gln)
(CID 5961)
0.72 0.27 1.62 0.72 0.72 0.69 0.42 1.86 0.69 0.69
Lysine (Lys)*
(CID 5962)
232.41 136.62 481.02 231.6 233.25 278.52 133.56 133.56 277.56 279.48
Hydroxyproline (OH-Prol)
(CID 5810)
365.85 222.81 731.04 364.95 366.78 405.99 232.65 954.00 405.15 406.8
Pipecolic acid (PiPA)
(CID 849)
94.32 64.62 228.27 228.27 94.53 99.78 61.59 178.02 99.54 100.05
Abscisic acid (Aba)
(CID 5280896)
6.90 2.25 21.24 6.87 6.93 7.20 3.09 14.67 7.17 7.23
Alaninea (Ala)**
(CID 5950)
238.95 124.08 408.24 238.32 239.55 282.66 174.18 453.96 281.67 283.62
Argininea (Arg)
(CID 6322)
71.52 38.79 129.27 71.34 71.70 77.58 36.45 139.08 77.43 77.76
Aspartic acida (Asp)*
(CID 5960)
328.26 89.07 1821.69 324.3 332.22 538.74 75.75 1300.23 534.75 542.76
Carnosin (Carn)
(CID 439224)
1.29 0.03 3.72 1.29 1.29 1.17 0.30 3.06 1.14 1.17
Citrullinea (Cit)
(CID 9750)
22.77 10.80 51.75 22.68 22.83 25.44 12.54 40.47 25.38 25.50
Glutamic acida (Glu)
(CID 33032)
129.99 86.82 187.38 129.75 130.23 127.32 77.25 207.66 126.99 127.65
Glycinea (Gly)***
(CID 750)
151.35 87.51 269.13 151.08 151.62 180.96 107.64 359.16 180.06 181.89
Histidine (His)***
(CID 6274)
79.80 39.30 221.19 79.62 80.01 96.15 62.01 200.91 95.91 96.39
Leucinea/Isoleucine (Leu/Ile)**
(CID 6106/CID 6306)
114.18 68.67 232.47 113.82 114.54 139.74 75.96 272.31 139.41 140.1
Methyl-Histidine (MeHis)
(CID 64969)
9.03 3.66 49.77 8.97 9.09 8.94 3.57 22.92 8.91 9.00
Methioninea (Met)*
(CID 6137)
14.58 2.97 78.60 14.55 14.64 16.92 9.87 35.28 16.86 16.98
Ornithinea (Orn)
(CID 6262)
53.43 31.83 88.08 53.34 53.55 55.65 26.49 108.36 55.53 55.77
Phenylalaninea (Phe)
(CID 994)
58.65 37.14 111.57 58.50 58.83 61.23 37.38 132.78 61.08 61.38
Proline (Pro)
(CID 8988)
186.15 98.13 408.87 185.52 186.78 178.92 112.38 520.41 178.35 179.52
Sarcosine (Sarc)*
(CID 1088)
85.20 55.44 178.29 84.99 85.38 99.90 51.09 215.07 99.51 100.32
Serine (Ser)
(CID 5951)
96.90 50.67 163.29 96.69 97.14 92.79 54.63 205.92 92.55 93.03
Taurine (Tau)
(CID 1123)
2.46 1.23 5.19 2.46 2.49 2.31 0.90 5.43 2.28 2.31
Threonine (Thr)**
(CID 6288)
11.73 6.09 22.68 11.7 11.76 14.01 7.35 25.65 13.98 14.04
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(none significantly) in colorectal carcinoma patients com-
pared to healthy controls. Several amino acids were non-
normally distributed across both study groups (Table 2).
3.2 Correlations
To evaluate the correlation of the significantly different
amino acids with the health state and with each other,
we computed point-biserial correlations (rpb) and Kendall’s
τb, respectively. rpb ranged between –0.38 and 0.10
(with P \ 0.05 for rpb



 0:199), Kendall’s τb between
–0.01 (P = 0.57) and 0.54 (P \ 2.2 9 10−16). The results
are limned in Fig. 1.
3.3 Modelling
As we conjectured that the use of combinatory markers
including multiple amino acids and/or CEA could yield
additive effects and outclass single amino acids and/or
CEA (Schneider et al. 2002; Wild et al. 2010), we built
combined models to evaluate their selectivity in compari-
son with single amino acids and CEA. To control for
multicollinearity, which is a significant restraint for logistic
regression (Leigh 1988), we performed PCA following
power transformation on the significantly different amino
acids and processed the resulting principal components
(PCs) as well as the corresponding single amino acid
concentrations and CEA by binary logistic regression
modeling. The best PCA-based model comprised CEA and
PC1, the best amino acid concentration-based model CEA,
Glycine, and Tyrosine with a slightly better fit (ΔBIC–2.8).
3.4 Receiver–operator-characteristics analysis
We used the single amino acid concentrations as well as the
predictors gained from the two best-fitting models for
AUROC analysis. The results are displayed in Table 3 for
the amino acids and in Fig. 2 for the predictors compared to
CEA. The best-discriminating model comprised CEA,
Glycine, and Tyrosine (AUROC 0.878, 95% CI 0.815–
0.941), followed by the model comprising CEA and PC1
(AUROC 0.844, 95% CI 0.773–0.916), CEA alone (AU-
ROC 0.794, 95% CI 0.712–0.877) and Glycine (AUROC
0.707, 95% CI 0.613–0.801) as the best discriminating
single amino acid. Both predictor models were not signif-
icantly different, the CEA, Glycine, and Tyrosine model,
however, differed highly significant from CEA alone
(P = 0.015).
3.5 Non-inferiority and superiority testing
Since significant difference is not an adequate measure of
non-inferiority or superiority, we performed sequential
testing for both with an a priori-defined acceptance crite-
rion (equivalence limit) of δL = 5% ΔAUROC. We computed
the lower and upper limits of the (100 − 2 δL)% bootstrap
confidence interval (0.0239–0.1422) of the estimated
ΔAUROC (B = 999) as proposed by Liu et al. (2006).
Referring to Mascha (2010) we deduced non-inferiority in
a first step, and—as the lower CI of ΔAUROC is [0—
inferred superiority of the model containing CEA, Glycine,
and Tyrosine over CEA alone thereafter.
4 Discussion
We found the concentrations of 11 out of 26 serum amino
acids as significantly different between CRC patients and
healthy controls. To additionally evaluate the diagnostic
potential of our results, we applied a bioinformatic pipeline
comprising common standard test statistics as well as
AUROC analysis followed by non-inferiority/superiority
Table 2 continued
Colon cancer patients (n = 59) [μmol/l]a Controls (n = 58) [μmol/l]a
Median Range Median CI 95% Median Range Median CI 95%
Minimum Maximum Low High Minimum Maximum Low High
Tryptophan (Trp)
(CID 6305)
7.65 3.57 21.21 7.62 7.65 7.68 3.09 17.28 7.65 7.68
Tyrosinea (Tyr)*
(CID 6057)
46.08 27.27 69.96 45.96 46.23 50.52 32.64 92.79 50.40 50.64
Valinea (Val)*
(CID 6287)
231.99 132.99 364.50 231.51 232.50 260.49 158.49 401.97 260.07 260.94
Significance of group differences is given by * for P\ 0.05, ** for P\ 0.01 and *** for P\ 0.001 (Wilcoxon-test); Italics show significant
deviation from normal distribution (Anderson–Darling-test, computed on the original data). Median, minimum, maximum, and the 95% CI of the
median are computed on the bootstrapped data (B= 999). Concentrations are μmol/l for amino acids quantified via internal standard (marked by a)
and relative for all others (cf. Brauer et al. 2011). Metabolites are identified by their PubChem Compound ID (CID)
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testing and found a model including CEA, glycine, and
tyrosine as best discriminating and superior to CEA alone
with an AUROC of 0.878 (95% CI 0.815–0.941).
The rationale of our study was to detect and evaluate
alterations of the amino acid profile in CRC patients as a
potential source of complementary metabolic markers by
means of standardized preanalytics, a routinely applicable
analytical method, and a computational procedure, which
allows statistically sound statements (Walker and Nowacki
2010) on the diagnostic surplus value.
The recent methodological advancements in the rapidly
emerging field of clinical metabolomics preceded numer-
ous studies investigating metabolic signatures of colorectal
cancer. A variety of different mass-spectrometric platforms
has been applied and yielded different marker analytes.
Comparable to our results, Qiu et al. (2009) also found
serum lysine, leucine, threonine decreased, valine, and
tyrosine decreased [the latter with both applied techniques,
Gas chromatography time-of-flight mass spectrometry
(GC-TOF MS) and Ultraperformance liquid chromato-
graphy-quadrupole time-of-flightmass spectrometry (UPLC-
QTOF MS)], Ma et al. (2009) valine, threonine and glycine
significantly decreased in CRC patients using GC-MS.
Denkert et al. (2008) found in a comprehensive study alanine,
methionine, threonine, leucine, isoleucine, valine, and less
significantly also glycine and lysine (GC-TOFMS) increased
in human CRC tissues, Chan et al. (2009) as well as Tessem
et al. (2010) [bothwith High-resolutionmagic angle spinning
nuclear magnetic resonance spectrometry (HR-MAS NMR)]
and Hirayama et al. (2009) [Capillary electrophoresis time-
of-flight mass spectrometry (CE-TOF MS)] found glycine,
and Ong et al. (2010) [Gas chromatography mass spec-
trometry (GC-MS)] methionine and tyrosine elevated in
CRC tissue samples, whereas Ma et al. (2010) (also with
GC-MS) comparing pre-/postoperative samples found
serum valine decreased and tyrosine increased after surgery.
Another study by Qiu et al. (2010) focused on urinary
metabolites and revealed lower histidine concentrations in
CRC urine samples. The comparability of these studies
among each other and with our study is limited due to dif-
ferent analytical techniques, sample material as well as
Table 3 Amino acid AUROCs and their 95% CIs for the differen-
tiation of colon cancer patients and controls
Amino acids AUC 95% CI
Low High
Glycine 0.707 0.613 0.801
Histidine 0.691 0.593 0.788
Alanine 0.677 0.580 0.774
Leucine/Isoleucine 0.653 0.551 0.754
Threonine 0.645 0.544 0.746
Tyrosine 0.636 0.536 0.737
Methionine 0.633 0.532 0.735
Valine 0.625 0.521 0.728
Lysine 0.624 0.522 0.725
Aspartate 0.622 0.520 0.724
Sarcosine 0.617 0.515 0.719
Arginine 0.594 0.490 0.697
Hydroxyproline 0.574 0.467 0.681
Pipecholic 0.568 0.463 0.673
Phenylalanine 0.568 0.463 0.672
Carnosin 0.558 0.452 0.663
Citrullin 0.554 0.447 0.660
Methylhistidine 0.536 0.430 0.642
Glutamine 0.530 0.424 0.635
Ornithine 0.527 0.420 0.634
Taurine 0.523 0.414 0.633
Abscisic acid 0.521 0.415 0.627
Tryptophane 0.506 0.400 0.612
Serine 0.506 0.399 0.612
Glutamine 0.485 0.378 0.591
Proline 0.463 0.357 0.569
AUROCs and 95% CIs for the different amino acids with respect to
the discriminatory power between colon cancer patients and healthy
controls
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p−value (ROC) = 0.11865 for CEA & Gly & Tyr vs. CEA & PC1
p−value (ROC) = 0.12946 for CEA & PC1 vs. CEA
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Fig. 2 ROC curves, 95% confidence bands (B = 999) and AUROCs
for CEA (red), the model consisting of CEA and principal component
1 (PC1 orange), and the model consisting of CEA, glycine, and
tyrosine (green). Sensitivity and specificity and their 95% confidence
intervals (B = 999) are given for the best thresholds and denoted by
(☩). P-values between AUCs are computed according to DeLong
et al. (1988) as described in the Sect. 2
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provenience, and patient classificators. Actually, there is
no published study comparing MS/MS-based serum
amino acid profiles of CRC patients and controls (Wang
et al. 2010). Additionally, the investigations of Ma et al.
(2010) and Qiu (2009) primarily aimed at the detection of
significant differences of the focused metabolites and not at
the evaluation of their diagnostic selectivity by canonical
methods like (Area under the) receiver–operator-charac-
teristics [(AU)ROC] analysis, as e.g. Ritchie et al. (2010)
performing Fourier transform ion cyclotron resonance mass
spectrometry (FTICR-MS) experiments and Chan et al.
(2009) performing HR-MAS NMR analyses did for ultra
long-chain fatty acids and tissue samples, respectively.
In both of these last-mentioned studies the discrimi-
nating analytes were, as “standalone”-markers or as
OPLS-DA-models, evaluated independently from the con-
ventional tumor marker CEA and their equivalence was not
surveyed.
Despite the limited comparability of the above-men-
tioned investigations with our study, the eleven significantly
decreased amino acids we detected were—except for sar-
cosine, and with varying significance—also identified as
marker metabolites for CRC in other studies.
The best discriminating amino acid glycine (AUROC
0.707), which was also found by Ma et al. (2009) and
Tessem et al. (2010), is an important intermediate in the
folate metabolism, which is especially altered in colon
cancer (Stover and MacFarlane 2008). Due to its recently
demonstrated bowel-protective effects and its easy appli-
cability it is also a highly interesting candidate for
therapeutic approaches (de Aguiar Picanco et al. 2011).
In biomarker research, it is a common practice to ana-
lytically determine marker molecules, compute the
statistical significance of their differences between groups
and to perform e.g. PCA-based analyses resulting in rota-
ted, non-linear, and non-retraceable (and therefore non-
comparable), but stunningly separating “component plots”,
leaving the reader alone with their interpretation. Only few
studies implemented AUROC analyses (Chan et al. 2009;
Ritchie et al. 2010) and none evaluated non-inferiority/
superiority. It is a core task and competence of laboratory
medicine, not only to investigate potential biomarkers, but
also to generate lucid test characteristics, which allow the
comprehensible interpretation of their diagnostic value and
their translation into clinical practice. Therefore, we aug-
mented our study by four add-ons: first, we generated
robust estimates for summary statistics of the amino acid
concentrations to facilitate comparability with other studies
despite the relatively small number of samples. Second, we
integrated the anyway available CEA concentrations into
BIC-based logistic regression modeling to utilize its aux-
iliary selectivity. Third, we compared amino acid
concentrations themselves with the typically used principal
components thereof and—fourth—specified the non-infer-
iority/superiority of our models compared to the
conventional tumor marker CEA based on AUROC
analyses.
Tyrosine was identified as marker metabolite by Qiu
et al. (2009), Ma et al. (2010, 2009), Vecer et al. (1998),
and Ong et al. (2010) and associated with cancer-related
alterations of the TCA cycle by Hirayama et al. (2009), but
in contrast to glycine, it displayed inferior selectivity with
an AUROC of 0.636 in our study. However, combined with
CEA and glycine, it surprisingly is part of the overall best
discriminating model, suggesting that its contribution to the
selectivity of the model features aspects, which are dif-
ferent from or stronger than other amino acids, even if the
latter (e.g. histidine or alanine) individually are stronger
discriminators. Interestingly, the model comprising the two
amino acid concentrations was slightly more selective than
that based on PCA, inferring that variance-based tech-
niques—despite their frequent application—might not
always yield optimal classifications.
Even though the AUROCs of the best-discriminating
amino acids almost reach the range of CEA, they are of
limited use as single discriminators. In combination with
the conventional tumor marker CEA, which had an AU-
ROC (0.794) comparable to the recent literature (Wild
et al. 2010), glycine and tyrosine, however, introduced a
surplus of 8%, suggesting that—regarding their AUROCs
of 0.707 and 0.636 as single markers—their principal value
might be of additive nature and be missed when routinely
available CEA concentrations are not taken into account.
Besides these emboldening results, there are some lim-
itations to consider: whereas the determination of glycine
and tyrosine is based on isotope labeled internal standards
and of quantitative nature, the concentrations of several
other amino acids (cf. Table 2) have to be considered as
relative. For AUROC analyses, this might not be relevant,
since deviations affect both, controls and patients. None-
theless, direct comparisons with other studies are limited
for these parameters. Another criticism might arise from
the considerable overlap of the amino acid concentrations
between patients and controls as outlined by Issaq et al.
(2011) reviewing a metabolomic tumor marker study of
Kim et al. (2010) and denying potential use of the analytes
displayed there as biomarkers or for population studies.
However, applying the same standards on established
tumor markers, even CEA would inevitably fail. To mini-
mize this inherent overlap problem, we generated
multiparametric (and thereby multidimensional) models
(Robin et al. 2009; Wild et al. 2010). A third constraint is
implicated in our dichotomous study design consisting of
two well-separated cohorts, colorectal tumor patients on
the one and healthy controls on the other side. This pilot
study design is suited to maximize differences between
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both groups to enhance pre-test probability, but it cannot
deliver differentiation between CRC and e.g. inflammatory
bowel diseases. Along with the size of the cohort differ-
ences the statistical power is diminishing and the number
of study participants must be raised. With our preliminary
study we tried to find an optimal significance of the results
balancing study size and study group dissimilarity.
5 Concluding remarks
We analyzed 117 highly standardized serum samples and
generated amino acid profiles by applying a relatively
simple high-throughput mass-spectrometric technique. In
addition to the common reporting of the significance of the
concentration difference between groups and PCA-based
modeling, our bioinformatic pipeline included (AU)ROC
analyses, integrative BIC-based logistic regression model-
ing and non-inferiority/superiority testing to exemplarily
and numerically determine the diagnostic surplus value for
the clinician and to avoid the ambiguity remaining with a
significant difference. In comparison with the conventional
tumor marker for colorectal cancer CEA, our model addi-
tionally containing glycine and tyrosine was superior.
Further large-scale studies are necessary to elucidate the
potential of this model also to discriminate between cancer
and potential differential diagnoses.
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